Azenta Inc
azenta.comAzenta Inc (NASDAQ: AZTA) is a life sciences company that provides sample management products, services, and genomic analysis to pharmaceutical, biotechnology, academic, and government customers globally. Revenue comes from two segments: Sample Management Solutions, which sells automated storage systems, cryogenic freezers, sample tubes, consumables, and sample repository services; and Multiomics, which provides gene sequencing, gene synthesis, and related genomic services. Azenta reported $593.8 million in total revenue for FY2025, up from $573.4 million in FY2024. The company generated an operating loss of $26.8 million in FY2025, though interest income of $18.8 million partially offset that loss. Founded in 1978 as Brooks Automation Inc., the company exited semiconductor automation via a $2.9 billion divestiture in February 2022 and renamed itself Azenta in December 2021. It serves approximately 14,000 customers globally as of the FY2025 10-K filing. As of September 30, 2025, the company held approximately $119.6 million in cash equivalents denominated in foreign currencies.
Products & Services
Sample Management Solutions segment: automated stores, cryogenic LN2 vapor-based freezers, automated sample tubes (2D-coded, dual-coded, tri-coded), consumables (racks, tubes, caps, plates, foils), instruments (labeling, bar coding, capping, de-capping), controlled rate thawing devices, and sample repository services including storage and transportation. Multiomics segment: gene sequencing, gene synthesis, and related genomic services delivered through a network of 14 laboratories across the United States, China, United Kingdom, Japan, and Germany.
Revenue Model
Azenta generates revenue through two channels: product sales (automated storage hardware, cryogenic systems, sample tubes, consumables, and instruments) and service fees (sample repository storage, transportation services, gene sequencing, and gene synthesis). Revenue is recognized on both transactional product sales and service contracts.
Customers & Markets
Approximately 14,000 customers globally as of the FY2025 10-K. End markets include top pharmaceutical and biotechnology companies, clinical research and therapy development hospitals, early-stage biotech companies, and academic and government institutions.
Geographic Exposure
Operations and sales span the United States, United Kingdom, Germany, Canada, China, Singapore, Japan, and other international markets. A significant portion of products is sold outside the United States, including in China. As of September 30, 2025, approximately $119.6 million of cash and cash equivalents were held in foreign currencies. Foreign subsidiary sales are primarily denominated in local currencies, creating exposure to currency fluctuation risk.
Financial Snapshot
Loading...
